Europe
Allele Biotechnology and Pharmaceuticals filed lawsuits claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their COVID-19 treatments.
A few days ago, CNBC reported that five patients, three in Moderna’s and two in Pfizer’s Phase III trials, had experienced more severe, although transient side effects.
Together, the university and AVROBIO will look into an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
“We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.
“AMAG’s category-leading treatments are strong strategic complements to our existing therapeutic portfolio,” said Michael Porter, Covis’ chief executive officer.
AstraZeneca’s Phase III COVID-19 vaccine study in the United States is being further delayed due to the U.S. FDA wanting to take a more thorough look at information related to the trial.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
As part of its half-year 2020 financial report, the company announced significant restructuring that will include cutting 40% of its staff.
PRESS RELEASES